Sixth Pharmaceutical Company Charged In Ongoing Criminal Antitrust Investigation. Wonder why your drugs are so expensive. Look no further than corrupt drug companies like Taro, USA and their CEO’s.
This is the tenth case to be filed in the Antitrust Division’s ongoing investigation into the generic pharmaceutical industry. To date, five of the six companies charged—including Taro U.S.A.’s co-conspirator Sandoz Inc.—have admitted to their roles in antitrust conspiracies and resolved through DPAs under which they’ve collectively agreed to pay over $426 million in criminal penalties. In addition, four executives have been charged for their roles in fixing prices of generic drugs. Former Taro U.S.A. executive Ara Aprahamian was indicted in February 2020 and is awaiting trial. The other three executives have pleaded guilty, including a former senior executive at Sandoz Inc.
